Gritstone bio Inc (GRTS)

[Little Run]

Nice...$$$$!!!????????

[Little Run]

Nice...$$$$!!!????????

[Little Run]

Holy Fuck...Still just me!

[Little Run]

Hey King, yep that’s me!!!

[Little Run]

Hey King, yep that’s me!!!

[Little Run]

Well...she ran. Holding every last share and actually added today. Fuck, posting by myself isn’t cool or healthy. But it’s needed for validation of entry’s and exits in my little mind. Join us on Twits, arthura is my deal, but call me Art...Let’s F’n Go!!!!

[Little Run]

OK. In @$1.78 and it’s time to rip some F’n faces off!!! Let’s Go!!!

[FROZENFLAME]

Buying pressure on, breakout on the way .
$GRTS

[FROZENFLAME]

Wow huge bid 50K@$7 = $350k !!!
Slowly but surely
$GRTS

[FROZENFLAME]

Adding the dip, very cheap down here .
$GRTS

[FROZENFLAME]

https://hcwevents.com/bioconnect/

[FROZENFLAME]

Dip and rip !
$GTRS

[FROZENFLAME]

Tomorrow should be interesting,
Wishful thinking, short covering tomorrow and people trying to buy before Monday 1/10-1/13 conference, l like the idea lol .

https://hcwevents.com/bioconnect/

[FROZENFLAME]

$6.85 a new high for today, let’s go .

[FROZENFLAME]

Next round coming $7s, should be easy from here, she’s trying, breakout on the way IMO .
$GRTS

[FROZENFLAME]

Looks like it, can’t wait until Monday
https://hcwevents.com/bioconnect/

[dealerschool2006]

maybe today will be bottom...we will see where GRTS goes from here...

[FROZENFLAME]

Almost 50% of the float traded in the last two days, getting very interesting .
$GRTS

[FROZENFLAME]

Adding a little bit more down here !!

[FROZENFLAME]

Never seen something like this, stock down 50% from yesterday good news, and the company lost $350 million dollars of market cap, market insane, watching very closely !

[FROZENFLAME]

That’s crazy, crazy market, I got some on the dip hopefully it will recover, it should .

[dealerschool2006]

GRTS has positive results yet pps dropped 42% ... https://finance.yahoo.com/news/gritstone-announces-positive-clinical-results-120000485.html

[conix]

"Unmet Needs" Biotechs



CUBT

[jondoeuk]

Slides https://ir.gritstonebio.com/static-files/f529bc1e-fe58-43b5-8db8-1a0aeeb820b4

[jondoeuk]

ESMO webcast https://lifesci.rampard.com/WebcastingAppv5/Events/Registration/registration.jsp?Y2lk=MTM5OQ==&Y2lk=MTM5OQ==

[IH Market Vision [Andrew]]

GRTS and EDIT Biotech Stock Plays Update | Big Events Coming Up!

I chat about some recent events and news with Gritstone ($GRTS) and Editas ($EDIT) - two very exciting biotechnology companies doing work in a variety of treatments like immunotherapy & gene editing.



Watch on YouTube

[jondoeuk]

Upcoming KOL webinar

Gritstone will be hosting a KOL webinar on our #neoantigen oncology programs for colorectal cancer next Wednesday, August 18 at 11 a.m. ET. To learn more or to register, read the press release here: https://t.co/ldUHuhRTV2 pic.twitter.com/hBYGzV7vdx

— Gritstone bio (@gritstonebio) August 12, 2021

[jondoeuk]

At ESMO, Dr. Catenacci will give an oral presentation entitled: Clinical outcomes and immune responses in a Phase 1/2 study of personalized, neoantigen-directed immunotherapy in patients with advanced MSS-CRC, GEA and NSCLC.

[Whalatane]

Thx for the link
Kiwi

[roofus krile]

1/23/2021 Forbes: "Brazil's Covid REINFECTIONS Is A Warning To The World" https://www-forbes-com.cdn.ampproject.org/v/s/www.forbes.com/sites/williamhaseltine/2021/01/22/this-devastating-covid-19-outbreak-in-brazil-is-a-warning-for-the-rest-of-the-world/amp/?amp_js_v=a6&_gsa=1&usqp=mq331AQHKAFQArABIA%3D%3D#aoh=16113482209905&referrer=https%3A%2F%2Fwww.google.com&_tf=From%20%251%24s&share=https%3A%2F%2Fwww.forbes.com%2Fsites%2Fwilliamhaseltine%2F2021%2F01%2F22%2Fthis-devastating-covid-19-outbreak-in-brazil-is-a-warning-for-the-rest-of-the-world%2F

[Fress]

sold half my stash 2000 shares of GRTS at $32.00 parlaying those profits into PDSB company thats trading 1/20th market cap of GRTS.


$GRTS

[jondoeuk]

COVID webcast https://wsw.com/webcast/cc/grts5/1449630

[ClayTrader]

* * $GRTS Video Chart 01-20-2021 * *

Link to Video - click here to watch the technical chart video

[Fress]

second generation covid T cell vaccine & long antibody response is getting a lot attention now.


$GRTS 1.1 billion market cap
$PDSB 60 million market cap


$GRTS

[Docstemcell2020]

Yeah baby

[ClayTrader]

* * $GRTS Video Chart 01-19-2021 * *

Link to Video - click here to watch the technical chart video

[Rogerthat1]

Sorry meant 40K shares. Not dollars lol

[Rogerthat1]

Added $40K here today. Will swing for huge upside imo $GRTS

[Rogerthat1]

Tradable Float is tiny. 80% of Os locked up with tutes. When they let this one run, watch out imo. Cash runway into Q3 2021. $GRTS

[sick nam vet]

wow,this one is a traders wet dream,down to 4.00 from 8.00 with no apparent reason Decent news and nothing bad going on.Major short attack.

[jondoeuk]

ASCO: Personalized viral-based prime/boost immunotherapy targeting patient-specific or shared neoantigens: Immunogenicity, safety, and efficacy results from two ongoing phase I studies.

[CalMustang]

Thank you for the update!

[jondoeuk]

Here is the webcast (Q&A as well) https://jpmorgan.metameetings.net/events/hc20/sessions/29771-gritstone-oncology/webcast

[CalMustang]

38th Annual J.P. Morgan Healthcare Conference
16 Jan 2020 At 8:00 AM PST

https://jpmorgan.metameetings.net/events/hc20/general_signin

[Pinkballer7]

might be some potential here

[swampboots]

Yes I see the value and am eager for them to defeat obstacles, yet is the Co. investable now? The cash burn is enormous and they do have ability to get royalties off platform but will they need more and more financing as they pivot on their proprietary gains before they have no cash worries? Best is a buyout, by top player who thinks together they have a pathway to accelerate progress by significant degrees.

[jondoeuk]

Based on my own DD (some of which is below) I have a small position. Currently, I think they are one of the leaders in the space. Whether this will change is going to be based on the webcast and data presented next month.

Neoantigens, are derived from random somatic mutations in cancer cells and are not present in healthy cells. Therefore, not only can you target them due to there being no pre-existing tolerance, but also there is very little risk of inducing autoimmunity [1-3].

In humans, there is a large amount of evidence showing that T-cells, which target these serve an important role in mediating clinical responses to a range of different immunotherapies such as anti-PD-1 mAbs [4].

However, two of the biggest challenges are identification and delivery. When it comes to the latter, the company is using a heterologous prime-boost regime [5]. The hope is by using this they are able to generate enough T-cells to impact the cancer. For the former they have their own platform (EDGE). It was tested against public methods as well as how both compared to another approach used by Dr. Rosenberg/NCI. The majority (19/26, 73%) of MHC Class I restricted neoantigens would be included with EDGE vs. only 9/26 (35%) with public tools [6]. They will try to prioritise clonal over subclonal neoantigens [7]. Last year a collaboration with BLUE happened and this somewhat helps with validation in my view [8].

Refs:
1 https://www.cell.com/trends/molecular-medicine/fulltext/S1471-4914(17)30147-8
2 https://science.sciencemag.org/content/348/6230/69.long
3 https://www.nature.com/articles/nature13988
4 https://www.nature.com/articles/nature13954
5 http://cancerres.aacrjournals.org/content/78/13_Supplement/724
6 https://www.nature.com/articles/nbt.4313
7 https://science.sciencemag.org/content/351/6280/1463
8 https://www.businesswire.com/news/home/20180823005039/en/bluebird-bio-Gritstone-Oncology-Announce-Strategic-Collaboration

[swampboots]

This is an exciting field, but very complicated: hard to find eligible specimens, excruciatingly challenging to prepare, and reliant on many undiscovered
tweeks to the environment increasing the accepting of a positive response.

I could become the leading expert and still not know which Co. has the "goods", and can qualify to ever be profitable. Yet I am very interested as somehow this "thing" (neoantigen) seems to hold a key place in the cancer "game".

[jondoeuk]

A new PR https://www.globenewswire.com/news-release/2019/11/05/1941153/0/en/Gritstone-Oncology-Announces-Data-on-Novel-Shared-Tumor-Specific-Neoantigens-Identified-by-its-EDGE-Platform-and-Contained-Within-its-SLATE-Immunotherapy.html and

Here is the poster https://ir.gritstoneoncology.com/static-files/29cba170-e7fe-4c45-a66b-a5893cfdf7a7

[jondoeuk]

The company will webcast an investor event with its executive management team on Friday the 8th, from 6:00-8:00 p.m. ET.

The event will focus on the company's clinical-stage immunotherapies, GRANITE (personalised) and SLATE (shared neoantigens), including an overview of the ongoing trials as well as the type of preliminary immunogenicity and safety data the company expects to have for presentation at the European Society for Medical Oncology’s Immuno-Oncology Congress (ESMO-IO) in Dec*. The studies are on-track for completion in 2020 with data expected in mid-2020. The company will also review the novel shared neoantigens contained within its first SLATE product candidate that will be presented at the SITC Conference earlier that day.

A live webcast will be available within the Investors & Media section of the website at https://ir.gritstoneoncology.com/investors/events An archived replay will be accessible for 30 days following the event.

* (Mini Oral session) 93O - First Results of Phase 1/2 Studies Evaluating Viral Vector-based Heterologous Prime/Boost Immunotherapy Against Predicted HLA Class I Neoantigens Demonstrate CD8 T-Cell Responses in Patients with Advanced Cancers